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ABSTRACT
Cisplatin is a widely prescribed anticancer drug,
which triggers cell death by covalent binding to a
broad range of biological molecules. Among cis-
platin targets, cellular RNAs remain the most poorly
characterized molecules. Although cisplatin was
shown to inactivate essential RNAs, including ribo-
somal, spliceosomal and telomeric RNAs, cisplatin
binding sites in most RNA molecules are unknown,
and therefore it remains challenging to study how
modifications of RNA by cisplatin contributes to its
toxicity. Here we report a 2.6A˚-resolution X-ray struc-
ture of cisplatin-modified 70S ribosome, which de-
scribes cisplatin binding to the ribosome and pro-
vides the first nearly atomic model of cisplatin–RNA
complex. We observe nine cisplatin molecules bound
to the ribosome and reveal consensus structural fea-
tures of the cisplatin-binding sites. Two of the cis-
platin molecules modify conserved functional cen-
ters of the ribosome––the mRNA-channel and the GT-
Pase center. In the mRNA-channel, cisplatin interca-
lates between the ribosome and the messenger RNA,
suggesting that the observed inhibition of protein
synthesis by cisplatin is caused by impaired mRNA-
translocation. Our structure provides an insight into
RNA targeting and inhibition by cisplatin, which can
help predict cisplatin-binding sites in other cellular
RNAs and design studies to elucidate a link between
RNA modifications by cisplatin and cisplatin toxicity.
INTRODUCTION
Cisplatin was discovered in 1965 as a toxic byproduct
of electrolysis from platinum electrodes, which suppressed
growth ofEscherichia coli cells (1). Soon thereafter cisplatin
was found to exhibit antitumor activity (2), and in 1978 it
was approved by the Food and Drug Administration as an
anticancer drug (2,3). Since then, cisplatin has become one
of themost widely prescribed chemotherapeutic agents used
to treat diverse types of cancer such as ovary, lung, head-
and-neck, germ-cell and bladder cancer (4–6).
In eukaryotic cells, cisplatin causes cell-cycle arrest and
induces apoptosis (7–10). For decades, the underlying
mechanism has been primarily attributed to cisplatin cross-
linking to purine nucleotides in chromosomal DNA, which
was shown to prevent the cellular replication machinery to
traverse through cisplatin–DNA adducts leading to apop-
totic cell death (7). This model, however, has been chal-
lenged by numerous studies demonstrating that cisplatin
toxicity can originate rather from multiple sources, in-
cluding modifications of proteins, small peptides, lipids
and RNA, than solely from modifications of chromosomal
DNA (7–11). In particular, cisplatin was shown to inacti-
vate a number of essential RNAmolecules, including RNA
components of translation, splicing machineries and telom-
eric RNA, indicating that RNAmolecules may represent an
underexplored class of pharmacologically relevant cisplatin
targets (12–17).
Despite the growing interest, experimental studies fo-
cused at elucidation of a link between RNA modifications
by cisplatin and its toxicity remain challenging. To this
end, RNA modifications by cisplatin have been studied
using ribosomal, transfer, messenger, spliceosomal, telom-
eric and other RNAs primarily by biochemical techniques,
which were aimed to identify cisplatin binding sites and de-
scribe the effect of cisplatin binding on RNA activity (12–
17). The only available crystal structures of RNA modi-
fied by cisplatin-derived Pt species are for tRNAPhe and
were determined at a relatively low resolution (18,19). These
studies roughly located cisplatin-binding sites in several
RNA molecules, but, none of them provided an accurate
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model of cisplatin–RNA interactions. Therefore, the under-
lyingmechanismof cisplatin recognition and inactivation of
RNA molecules has remained elusive.
Here we report 2.6A˚-resolution crystal structure of Ther-
mus thermophilus 70S ribosome modified by cisplatin-
derived Pt species. This is the first nearly atomic reso-
lution structure of Pt-RNA adducts following cisplatin
treatment of the ribosome. We observe nine cisplatin-
derived molecules bound to the ribosome and show that the
cisplatin-modified sites share common structural features,
which appear to determine specific cisplatin binding to a
very limited number of sites in the rRNAmolecules. Consis-
tent with previous biochemical studies, cisplatin targets two
universally conserved centers of the ribosome––the mRNA
channel and the GTPase activating center. Strikingly, in the
mRNAchannel, cisplatin forms simultaneous contacts with
the ribosome and the mRNA––a feature that has been re-
cently observed for the ribosome-targeting antibiotic ami-
coumacin A, which inhibits protein synthesis by tethering
mRNA to the ribosome (20). In summary, our study identi-
fies cisplatin-binding RNA motifs, provides a rationale for
the cisplatin-induced inhibition of protein synthesis and re-
veals an unexpected similarity between the anticancer drug
cisplatin and the ribosome-targeting antibiotics.
MATERIALS AND METHODS
Purification of Thermus thermophilus ribosomes and prepa-
ration of tRNAs
70S ribosomes from T. thermophilus and deacylated
tRNAiMet and tRNAPhe from E. coli were purified as previ-
ously described (21). SyntheticmRNAwith the sequence 5′-
GGC AAGGAGGUAAAAAUGUUCUAA-3′ was ob-
tained from Integrated DNA Technologies (Coralville, IA,
USA).
Crystallization and data collection
The ribosome complex with mRNA and tRNAs was
formed by programming 5 M 70S ribosomes with 10 M
mRNA and 20 M P- and A-site tRNA substrates, in the
buffer containing 5 mM HEPES-KOH (pH 7.6), 50 mM
KCl, 10 mM NH4Cl, and 10 mM Mg(CH3COO)2, and 6
mM -mercaptoethanol. Next, the cisplatin (dissolved in
dimethylformamide) was added to a final concentration of
500 M and the resulting mixture was left at room tem-
perature for additional 10 min. Next, crystallization was
initiated by mixing 3 l of the ribosome complex solu-
tion with 4 l of the buffer containing 100 mM Tris–HCl
(pH 7.6), 2.9% (w/v) PEG-20K, 7–12% (v/v) MPD, 100–
200 mM arginine and 0.5 mM -mercaptoethanol. Crys-
tals were grown in 10 days by the vapor diffusion method in
sitting drops at 19◦C and were stabilized as described pre-
viously (21). In the soaking experiment, cisplatin was not
included during complex formation and crystallization. In-
stead, it was included into the final crystal-stabilization so-
lution at 100 M concentration. This solution, containing
ribosome crystals and cisplatin, was left at room tempera-
ture for 12 h and then the crystals were frozen and used for
data collection. Diffraction data were collected using beam-
line 24ID-C at the Advanced Photon Source (Argonne, IL,
USA). A complete dataset for each ribosome complex was
collected using 0.979A˚ wavelength at 100K from multiple
regions of the same crystal using 0.3◦ oscillations.
Crystallographic data processing and model building
The raw data were integrated and processed using the XDS
software package (22). All crystals belonged to the prim-
itive orthorhombic space group P212121 with approximate
unit cell dimensions of 210A˚× 450A˚× 620A˚ and contained
two copies of the 70S ribosome per asymmetric unit. The
initial molecular replacement solutions were obtained by
rigid body refinement, followed by positional and individ-
ual B-factor refinement. The initial search model was gen-
erated from recently published high-resolution structure of
Tth 70S ribosome with bound mRNA, tRNAs and con-
taining all post-transcriptional modifications of the rRNAs
(PDB ID: 4Y4P) (23). Cisplatin modification sites in the
ribosome were identified using the unbiased electron den-
sity maps (Figure 1) together with the anomalous difference
Fourier maps (Supplementary Figure S1). The final model
of the cisplatin-modified 70S ribosome was generated by
multiple rounds of model building in COOT (24), followed
by refinement in PHENIX (25). For several cisplatin mod-
ification sites, the improved electron density maps revealed
conformation of individual chemical groups of the cisplatin
moiety, which enabled nearly atomic description of the
cisplatin–rRNA interactions. The statistics of data collec-
tion and refinement are compiled in Supplementary Table
S1. All rRNA nucleotides were renumbered according to E.
coli numbering system.
RESULTS
Cisplatin targets only a small fraction of rRNA bases
To gain insights into the cisplatin binding to the ribo-
some, we co-crystallized T. thermophilus 70S ribosomes
with the mRNA, tRNAs and cisplatin, and determined a
2.6A˚ resolution X-ray structure of cisplatin-modified ri-
bosome (Supplementary Table S1). The ribosome-bound
cisplatin-derived Pt species appeared as prominent peaks in
both the unbiased (Fo–Fc) and in the anomalous difference
electron density maps (Figure 1, Supplementary Figure S1
and Table S2).
Strikingly, the maps revealed only nine cisplatin-derived
Pt species in the entire ribosome, despite the fact that the
ribosome harbors nearly 2200 potential modification sites
(Supplementary Figure S2). Three of the observed moieties
are coordinated by the N7-atoms of adenine bases: A790
of the 16S rRNA (E. coli numbering is used throughout
the text; Figure 1A and D; Supplementary Figure S1), and
A1848 and A2531 of the 23S rRNA (Figure 1B, E and F;
Supplementary Figure S1). Five moieties are coordinated
by the N7-atoms of guanine bases at positions G1300 of
the 16S rRNA and G27, G425, A1606, G2220, G2221 of
the 23S rRNA (Figure 1, Supplementary Figure S1). One
cisplatin moiety is coordinated by the N-terminus of the ri-
bosomal protein L9 (Figure 1I). A small total number of
the cisplatin binding sites in the ribosome points to the high
specificity of RNA recognition by cisplatin.
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Figure 1. Cisplatin-binding sites in the ribosome. (A and B) Overview of cisplatin-modified residues (yellow spheres) in the large (A) and small (B) subunits
of the Thermus thermophilus 70S ribosome. The actual cisplatin-derived Pt species are shown as red spheres. Panels (C–I) show close-up views of the
cisplatin modification sites. The refined models of cisplatin-modified nucleotides are displayed in their respective unbiased electron density maps. Gray
mesh shows the Fo–Fc map after refinement with the entire cisplatin-modified nucleotides omitted (contoured at ∼3.0). Green mesh shows the Fo–Fc
electron density map after refinement with unmodified nucleotides (contoured at∼3.0). Carbon atoms are colored yellow, nitrogens––blue, oxygens––red,
platinums––magenta, chlorines––green.
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Cisplatin-binding sites share common structural features
Having determined several cisplatin modification sites in
the rRNAs, we attempted to elucidate what underlies spe-
cific binding of cisplatin to these particular sites. First, we
assessed whether reactivity of N7-atoms in purine bases
is determined by their spatial accessibility to the cisplatin
molecule. For this purpose, we used the structure of a non-
modified 70S ribosome from T. thermophilus and measured
accessibility of all N7-atoms to a 2.2A˚-radius sphere, which
corresponds to the size of the cisplatin molecule (see ‘Ma-
terials and Methods’ section). We found that the 70S ribo-
some has more than 2200 N7-atoms with a comparable or
higher solvent exposure than those of the nine actual mod-
ification sites (Supplementary Figure S2). This result indi-
cates that selective modification of certain RNA bases by
cisplatin is not defined solely by the spatial accessibility of
their N7-atoms.
Previously, cisplatin was shown to target predominantly
non-Watson–Crick RNA segment (26,27), and our analysis
confirms this finding for modification of rRNAs (Supple-
mentary Figure S3). Among cisplatin-modified rRNA nu-
cleotides, only one (G425 of the 23S rRNA) forms a canon-
ical G-C pair and is located within a regular A-form helix,
whereas all others residewithin bulges (A1878 inH68 of 23S
rRNA), helical junctions (G1300 in h41/h42 and G1606 in
H49/H51), internal loop (G27 in H2), hairpin loops (A790
in h24 and A2531 in H91) or an A-form helix distorted by
a G-U pair (G2220/G2221 in H79) (Supplementary Figure
S3). These and previous data suggest that irregular RNA
geometry leads to structural folds that favor cisplatin bind-
ing, however identity of such folds was unclear.
To address this question, we analyzed the immediate sur-
roundings of the cisplatin moieties within the ribosome.
One common property, which we observed in all of the
cisplatin-binding sites, is that cisplatin interactions with the
ribosome are never limited to N7-atoms of purine bases,
but involve additional contacts with adjacent rRNA nu-
cleotides (Supplementary Table S2). We also found that
these contacts are strikingly different for cisplatin moieties
coordinated by guanines versus adenines.
Cisplatin modifications of guanine bases
Guanines coordinate cisplatin moieties in cooperation with
surrounding rRNA backbone phosphates (Figure 2A and
C; SupplementaryTable S2). For instance, the cisplatinmoi-
ety bound to the N7-atom of G1300 in 16S rRNA forms
additional contacts with the adjacent phosphates of A1332
and A1333 via its amino groups (Figure 2A). Similar cis-
platin coordination is observed for other guanine bases in
the ribosome (Figure 2C and Supplementary Table S2). Im-
portantly, the close positioning of phosphates to N7-atoms
of guanine bases results from highly distorted RNA folds,
rationalizing why efficient cisplatin coordination requires
non-Watson–Crick geometry of RNA. We made one cu-
rious observation about modification of guanine bases by
comparing the ribosome structures before and after treat-
ment with cisplatin. If the structures of cisplatin-modified
and non-modified ribosomes are superimposed, the cis-
platin derivatives overlap with the hydratedMg2+ ions (Fig-
ure 2B and D). Furthermore, these Mg2+ ions in the non-
modified ribosome directly interact with the guanine N7-
atoms and form similar contacts with rRNA as cisplatin
moieties in the cisplatin-modified ribosome (Figure 2B and
D).
It is important to note that in the structure of non-treated
ribosome there are about 100 guanine N7-atoms, which co-
ordinate hydrated magnesium ions in their inner spheres,
but which are not modified by platinum in the structure
of cisplatin-modified ribosome (Supplementary Figure S4).
This fact indicates that inner-sphere coordination of hy-
drated Mg2+ ions is not the only factor that determines
high reactivity of guanine bases with cisplatin. However, be-
cause Mg2+-coordinating guanines are rare (∼7% of gua-
nines in the rRNA structure) (Supplementary Figure S4A
and B), and all five modified guanines do coordinate Mg2+
ions in the structure of the non-treated ribosome, the abil-
ity to coordinate Mg2+ ions appears to be an important cri-
terion predicting guanine reactivity with cisplatin. Impor-
tantly, this criterion suggests that guanines that do not di-
rectly coordinateMg2+ ions should not efficiently react with
cisplatin.
Cisplatin modifications of adenine bases
Unlike guanine bases, adenine bases coordinate cisplatin
only if positioned immediately before the guanine base, in a
characteristic AG-motif (Figure 3A–D). In this AG-motif,
the N7-atom of the adenine base is covalently linked to
platinum, whereas the 3′-adjacent guanine base provides
its Hoogsteen edge (O6-atom) to interact with the cisplatin
amine (dashed lines in Figure 3A–C). Notably, all cisplatin-
coordinating AG-motifs in the ribosome share nearly iden-
tical geometry, which deviates from the ideal A-form RNA
geometry by the 15◦-turn of the G-base toward the A-base
(Figure 3E, compare ‘orange’ and ‘green’ structures). At
the same time, there are no apparent differences in the ge-
ometry of all AG-motifs between cisplatin-modified and
non-modified ribosome (Figure 3E, compare ‘orange’ and
‘blue’ structures) indicating that their distorted geometry is
likely the cause, and not the consequence, of cisplatin bind-
ing. Another notable similarity between the AG-motifs is
their location at the RNA–RNA or RNA–protein inter-
faces (Figure 3A-C; Supplementary Table S2): nucleotide
A790 of the 16S rRNA resides in the mRNA channel at the
rRNA/mRNA interface, where the cisplatin-modified nu-
cleotide contacts the mRNA molecule (Figure 3A); A1848
of the 23S rRNA resides at the 23S/16S rRNA interface,
where the cisplatin moiety lies in the direct vicinity of the
intersubunit bridge B7a (Figure 3B); and A2531 of the 23S
rRNA lies at the interface with the ribosomal proteins L6,
whose C-terminus is likely to contact the cisplatin moiety
(Figure 3C).
It is important to note, that in the ribosome structure
there are a total of 343 AG-sites, among which about 12 are
accessible to a cisplatin-size molecule and whose geometry
is close or equivalent to those of the cisplatin-modified AG-
sites (Supplementary Figure S4C andD). The fact that only
a small subset of theseAG-sites ismodified by cisplatin indi-
cates that the reactivity of these sites rather depends on their
immediate surroundings than solely relying on the particu-
lar AG-site structure or accessibility of N7-atoms. However,
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Figure 2. Cisplatin coordination by guanine bases resembles coordination of magnesium ions. (A and C) Side-by-side comparison of cisplatin-modified
guanine residues in 16S rRNA (light yellow) and 23S rRNA (light blue). Panels (B and D) show the same sites in the untreated 70S ribosome (PDB ID:
4Y4P (23)). Cisplatin-modified nucleotides are highlighted in yellow. The color coding for atoms is the same as in Figure 1. Note that cisplatin binding
is observed in idiosyncratic RNA folds, in which N7-atoms of purine residues normally coordinate magnesium ions (in the untreated ribosome) and are
located adjacent to the RNA phosphates capable of stabilizing the cisplatin moiety by electrostatic interactions.
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Figure 3. Cisplatin coordination by adenine bases occurs in a characteristic AG-motif. (A–C) Side-by-side comparison of cisplatin-coordinating adenine
residues in 16S rRNA (A) and 23S rRNA (B and C). Color coding is the same as in Figure 2. Note that all three cisplatin-modified adenine residues are
located immediately upstream of the guanine residues in a characteristic AG-motif. (D) Superposition of the three AG-motifs shown in panels (A–C) reveal
their nearly identical geometries. (E) Superposition of A1848-G1849 (23S rRNA) before (blue) and after cisplatin modification (orange) and with the ideal
A-form RNA helix (green). Superposition is based on the first adenine nucleotide in each AG-motif. Note that in the untreated 70S ribosome nucleotides
A1848-G1849 deviate significantly from the ideal A-form RNA helix and do not change their relative spatial orientation as a result of modification of
A1848 by cisplatin.
because adenine modifications by cisplatin are observed ex-
clusively within a rare type of AG-sites, the structure of this
AG-site may help predict whether an adenine base is likely
to react with cisplatin or not.
Probing of RNA reactivity with cisplatin in a rapid soaking
experiment
We were curious to see if some of rRNA bases react with
cisplatin more rapidly than the others. For this purpose, we
soaked the pre-formed crystals of theT. thermophilus 70S ri-
bosomes, bound with mRNA and A-, P- and E-site tRNAs,
in a solution containing 100 M cisplatin and determined
a crystal structure at 2.8A˚ resolution (see ‘Materials and
Methods’ section, Supplementary Table S1). Analysis of the
electron density maps revealed that at much shorter incu-
bation time (12 h compared to 10 days) and overall lower
cisplatin concentration (100 M compared to 500 M) all
three adenine nucleotides, which were modified in the co-
crystallization experiment, were also modified in the soak-
ing experiment (Supplementary Table S2). Modification of
protein L9 by cisplatin was also present. However, no other
sites of modification by cisplatin were observed, suggesting
that adenine bases in the rRNA react faster with cisplatin
than the guanine bases.
Cisplatin targets conserved functional centers of the ribosome
Cisplatin inactivates protein synthesis in organisms ranging
from bacteria to mammals (28,29). In the current work, we
found that cisplatin targets several functional centers of the
ribosome including the mRNA channel, the GTPase acti-
vating center, the peptide exit tunnel, and the functionally
important bridge B7a between the two ribosomal subunits
(Figure 4), suggesting possible mechanisms of cisplatin-
mediated inhibition of protein synthesis.
In the small ribosomal subunit cisplatin targets the uni-
versally conserved nucleotide A790 of the 16S rRNA in
the mRNA channel (Figure 5A). At this location, cisplatin
forms an additional contact between the ribosome and the
mRNA (Figure 5B), suggesting that cisplatinmight stabilize
mRNA binding to the ribosomal P site and thereby inhibit
protein synthesis by preventing mRNA/tRNA transloca-
tion. Notably, the A790-modification site has a universally
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Figure 4. Cisplatin targets functional centers of the ribosome. (A) Cisplatinmodification site in the peptide exit tunnel (G26 of the 23S rRNA). (B) Cisplatin
modification sites in the mRNA channel (A790 of the 16S rRNA), at the intersubunit bridge B7a (A1848 of the 23S rRNA) and in the GTPase center
(A2531 of the 23S rRNA). 30S subunit is shown in light yellow, 50S subunit is in light blue. mRNA is shown in magenta and tRNAs are displayed in
green for the A site, in dark blue for the P site and in orange for the E site. Middle portion of the E-site tRNA is omitted for clarity. Cisplatin-modified
nucleotides are shown as yellow sphere with actual cisplatin-derived Pt species colored in red. The view in (A) is a transverse section of 70S ribosome. The
view in (B) is from the top after removing the head of the 30S subunit and protuberances of the 50S subunit, as indicated by the inset.
Figure 5. Cisplatin targets the mRNA channel in the ribosome. (A) Overview and (B) close-up view of the cisplatin modification site in the mRNA channel
(yellow with the cisplatin moiety in red), where cisplatin modifies the universally conserved base A790 and stabilizes contacts between the ribosome and
the mRNA (magenta). A-site tRNA is colored green, P-site tRNA––dark blue, E-site tRNA––orange. (C) Superposition of the 16S rRNA from Thermus
thermophilus (light yellow) in the vicinity of the nucleotide A790 with the homologous region of the 18S rRNA from Homo sapiens (light blue; PDB ID:
4V6X (43)). Superposition is based on the alignment of nucleotides 787–795 from helix 24 of T. thermophilus 16S rRNA with nucleotides 1055–1063 ofH.
sapiens 18S rRNA. High similarity of mRNA channels suggests that cisplatin is likely to target nucleotide A1058 of the 18S rRNA (homologous to A790
in 16S rRNA) in the human ribosome.
conserved structure, suggesting that the mRNA channel
could be modified by cisplatin in the same way in the ri-
bosomes from humans and other species (Figure 5C).
In the large ribosomal subunit, cisplatin targets residue
A2531 of the 23S rRNA, which contacts the GTPase acti-
vating center (A2662 in the sarcin-ricin loop) (Figure 6A).
In this position, the cisplatin moiety lies at the binding in-
terface of elongation factor G (EF-G) and clashes with
the C-terminal portion of ribosomal protein L6, suggesting
that cisplatin modification of A2531 could either alter EF-
G binding to the ribosome or affect GTP hydrolysis (Fig-
ure 6B). Notably, as is the case with the mRNA channel,
the GTPase activating center is highly conserved across all
species (Figure 6C), suggesting similar targeting of human
ribosomes by cisplatin.
Cisplatin targets two other functional sites in the large ri-
bosomal subunit––the peptide exit tunnel (G27 of the 23S
rRNA; Figure 4A) and the inter-subunit bridge B7a (A1848
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Figure 6. Cisplatin modification site near the GTPase activating center of the ribosome. (A) Overview and (B) close-up view of the cisplatin position in
the vicinity of the ribosome GTPase activating center. The structure of cisplatin-modified ribosome is superimposed with the structure of ribosome-bound
EF-G (green) (PDB ID: 4V5F (44)). Superposition is based on the alignment of the 23S rRNA. 30S subunit is shown in light yellow, 50S subunit is in
light blue. mRNA is shown in magenta and tRNAs are displayed in dark blue for the P site and in orange for the E site. tRNA for the A site is omitted
for clarity. The view in (A) is from the top after removing the head of the 30S subunit and protuberances of the 50S subunit, as indicated by the inset.
Note that cisplatin moiety of A2531 lies at the ribosome/EF-G interface in the immediate vicinity of the GTPase activating center (nucleotide A2662).
(C) Superposition of the 23S rRNA from Thermus thermophilus (light blue) in the vicinity of the GTPase activating center with the homologous region
of the 28S rRNA from Homo sapiens (green; PDB ID: 4V6X (43)). Note that due to extremely high conservation of the GTPase activating center, human
ribosomes are likely to be modified by cisplatin at the same site as bacterial ribosomes.
of the 23S rRNA; Figure 4B). Modification of these nu-
cleotides may hinder passage of the nascent polypeptide
through the tunnel, and affect inter-subunit rotation dur-
ing protein synthesis. However, both these sites are not con-
served between bacteria and eukaryotes, and therefore are
not likely to account for the inhibition of eukaryotic ribo-
somes by cisplatin.
Similarity between cisplatin and ribosome-targeting antibi-
otics
Protein synthesis can be inhibited by a number of small
molecules, which include many ribosome-targeting antibi-
otics. We couldn’t escape noticing that some of these an-
tibiotics, namely amicoumacin A and edeine, bind to the
ribosome in a close vicinity or even overlapping with the
cisplatin-binding site in the mRNA channel. Edeine––a
ribosome-targeting cationic peptide with potent anticancer
activity, ––binds the same 16S rRNA base as cisplatin
(A790) and partially overlaps with the cisplatin position,
suggesting that edeine and cisplatin binding to the ribo-
some are mutually exclusive (Supplementary Figure S5A)
(30–33). Another ribosome-targeting drug, amicoumacin
A, binds the mRNA channel a few angstroms away from
the cisplatin-binding site and inhibits protein synthesis by
forming simultaneous contacts with 16S rRNA andmRNA
and tethering mRNA to the ribosome (Supplementary Fig-
ure S5B) (20). Since cisplatin forms similar contacts with
the ribosome and the mRNA (Supplementary Figure S5B),
it is possible that cisplatin and amicoumacin A exhibit the
same inhibitory effects on protein synthesis.
DISCUSSION
Seeking to understand how the anticancer drug cisplatin
targets RNAmolecules, we determined the crystal structure
of the bacterial ribosome complexwith cisplatin. This struc-
ture provides the first high-resolution model of a cisplatin–
RNA adduct.
In this study, we identified nine cisplatin modification
sites in the ribosome and described precise positions and
interactions of cisplatin with ribosome components. Con-
sistent with previous studies of RNA modifications by cis-
platin, we observe selective binding of cisplatinmolecules to
non-Watson–Crick segments of ribosomal RNA (reviewed
in (11)). Notably, we observe a smaller number of modifi-
cation sites in the ribosome when compared with the re-
sults of MALDI-MS (additional sites in helix 69 of the
23S rRNA) (34), or primer extension techniques (additional
sites in helices 93, 95 and 96 of the 23S rRNA) (35). These
discrepancies might be caused by several factors. First, elec-
tron density maps allow identification of cisplatin-derived
Pt species only with occupancies above ∼50%. Biochemi-
cal techniques, however, are more sensitive and can detect
even residualRNAmodifications by cisplatin. Second,most
biochemical studies explore cisplatin reactions in solution,
in which ribosomes represent a mixture of different confor-
mations, whereas our work describes cisplatin binding to a
single conformation of the ribosome. Therefore, biochemi-
cal approaches can possibly detect more cisplatin modifica-
tion sites due to conformational variability of ribosome in
solution. Finally, the activity of cisplatin largely depends on
its activation through hydrolysis, when the chloride groups
of the cisplatin molecule are exchanged for water molecules
(Supplementary Figure S6). It is possible that the relatively
high concentration of chloride ions in our crystallization ex-
periments (160 mM compared with physiological levels at
4–12 mM) could reduce cisplatin activation and limit cis-
platin binding only to the most reactive sites in the ribo-
some. Apart from these discrepancies, our data agree with
biochemical studies that showed cisplatin binding with con-
served functional hairpins in the mRNA channel and in the
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vicinity of the GTPase activating center of the ribosome
(35,36).
Having visualized how cisplatin modifies ribosomal
RNA, we gained insights into specific recognition of RNA
by cisplatin. Our structures reveal the consensus structural
features of rRNA around the modification sites, in which
adenine bases coordinate cisplatin that are part of the char-
acteristic AG-motif, whereas guanine bases coordinate cis-
platin in cooperation with adjacent backbone phosphates
in distorted RNA folds and, in a manner, similar to inner-
shell coordination of magnesium ions. The latter observa-
tion corroborates with the previous finding that cisplatin
toxicity can be reduced bymagnesium ions, whichmask po-
tential modification sites (37). Our study confirms this no-
tion for guanine bases, but not for adenines, which normally
do not coordinate magnesium ions, as seen in the structures
of non-modified ribosomes. Collectively, comparative anal-
ysis of cisplatin-modified sites in the 70S ribosome provides
the first structure-based insight into specific targeting of
RNA by cisplatin. However, it is important to note that our
structural study may describe only one subset of the several
types of RNA modifications by cisplatin, in which Pt atom
of cisplatin moiety is, most likely, retained in its dichloro-
or mono-aqua form rather than the more prevalent in vivo
di-aqua form. It is also important to note, that our crystal
structures contain a number of AG-sites, which are struc-
turally similar to the ones that are modified, and Mg2+-
coordinating guanine bases, which are still not modified
by cisplatin. This observation points to the fact that there
might be other determinants of cisplatin specificity to only
particular sites in RNA structure. Despite these limitations,
both the structural AG-motif and Mg2+-coordination by
guanine bases represent the first and only known structural
signatures, whose presence in RNA correlates with cisplatin
reactivity. Both of these signatures illustrate that RNA re-
activity with cisplatin does not occur in RNA with ideal A-
helix geometry, but instead requires highly-distorted folds,
in which the cisplatin-derived Pt species forms extensive
contacts with RNA molecule. This observation is curious,
because highly distorted folds are the hallmarks of many
active centers in RNA molecules. The fact that both the
AG-motif and Mg2+-coordinating guanines are rarely oc-
curring in RNA structures creates promise for an efficient
prediction of cisplatin-reactive sites in cellular RNAs in the
future.
Our experiments, showing how cisplatin targets active
sites of the ribosome, extend our understanding of ribo-
some inhibition by small molecules. Together with recent
studies of several ribosome-targeting antibiotics, our study
changes our understanding of how small molecules act to
inhibit protein synthesis. Until recently, it was thought that
most of the ribosome-targeting drugs inhibit protein syn-
thesis by altering the conformation of the ribosome or by
preventing the proper binding of the ribosomal substrates.
This paradigm, however, was challenged by recent struc-
tural studies of antibiotics blasticidin S (38), amicoumacin
A (20), negamycin (39,40) and hygromycin A (41,42). These
antibiotics were shown to tether the ligands (such asmRNA
and tRNAs) to the ribosome or force their non-productive
conformations. It appears from the structure of cisplatin-
modified ribosome that the inhibitory activity of cisplatin
might rely on a similar mechanism, in which cisplatin stabi-
lizes interactions between the ribosome and the messenger
RNA.
To date, we lack a comprehensive understanding of how
cellular molecules are targeted by cisplatin. We also do
not fully understand how this targeting provokes cell death
and, in particular, how modification of RNA by cisplatin
contributes to cisplatin-induced toxicity. Therefore, detailed
knowledge of cisplatin binding sites in the ribosomal RNA
may not only provide a tool for prediction of modification
sites in other essential cellular RNAs, but will also help de-
sign experimental studies of the multifaceted nature of cis-
platin cytotoxicity.
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